Resultado de búsqueda
18 de nov. de 2022 · TP53, a crucial tumor suppressor gene, is the most commonly mutated gene in human cancers. Aside from losing its tumor suppressor function, mutant p53 (mutp53) often acquires inherent, novel ...
Inactivation de p53 dans les cancers. p53 est l’un des facteurs de transcription les plus étudiés du fait de son importance clinique. En effet, le gène TP53 est muté dans plus de la moitié des cancers sporadiques, et la plupart des autres cancers surexpriment Mdm2 ou Mdm4, les principaux régulateurs négatifs de p53. De plus, les mutations germinales de TP53 causent le syndrome Li ...
En el cáncer de próstata que tanta homología tiene con el de mama, Voeller et al (1994) observaron una baja tasa de mutación de la p53 26. Por todas estas razones se considera a la p53 como un gen supresor del cáncer y que junto con el oncogén RB son los genes supresores por excelencia.
As a component of the response to acute stress, p53 has a well established role in protecting against cancer development. However, it is now becoming clear that p53 can have a much broader role ...
p53, also known as Tumor protein P53, cellular tumor antigen p53 (UniProt name), or transformation-related protein 53 (TRP53) is a regulatory protein that is often mutated in human cancers. The p53 proteins (originally thought to be, and often spoken of as, a single protein) are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the ...
25 de oct. de 2023 · The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and growth of tumors. A gene that has been coined "the guardian of the genome," when inactivated, it can also play a role in the persistence, growth ...
Puesto que el gen p53 se puede encontrar mutado en casi todos los tipos de cáncer y aproximadamente el 50 % de todos los cánceres presentan mutaciones en el p53, se han desarrollado estrategias de terapia génica para suplementar las células cancerosas con este gen. La estrategia consiste en transferir el gen p53 funcional a las células cancerosas in vivo.
